Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.

Ono's antisense therapy is to begin its first pivotal trial.

The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April. 

The group’s first pivotal readout, in second-line pancreatic cancer, is coming.

The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.

But now it must show that varseta-M can move into a registrational trial.

The first fruit of a long-standing deal with Roche enters phase 1 in March.

The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer. 

After several discontinuations, a new ADC enters the clinic.